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In 2014, WHO approved a new strategy for the eli-
mination of tuberculosis,1 and recommended that 
countries adapt the strategy’s pillars—patient-cen-
tred care, supportive systems, and innovation—as 
appropriate to their local contexts. The need for a 
novel approach to elimination of tuberculosis in low-
incidence settings was further echoed in a second 
framework2 that laid out eight priority areas. Among 
the prescribed interventions were investment in new 
technologies and rapid drug-susceptibility testing to 
optimise treatments. In The Lancet Infectious Diseases, 
Timothy Walker and colleagues3 present an important 
study at the nexus of these areas, establishing 
a foundation for routine use of whole-genome 
sequencing in the mycobacteriology laboratory.
With the cost of sequencing a bacterial genome now 
similar to that of standard bacteriological assays such 
as drug-susceptibility testing (Pankhurst L, Oxford 
University, personal communication), a new framework 
is emerging in clinical microbiology, for which a single 
sequencing run is used to both diagnose an infection 
and predict its antibiotic susceptibility.4 Whole-genome 
sequencing is especially appealing for the tuberculosis 
laboratory—resistance in Mycobacterium tuberculosis 
arises largely because of point mutations, and whole-
genome sequencing can yield clinically actionable 
predictions of antibiotic susceptibility within days rather 
than the weeks or months of standard approaches. 
Ultimately, the ability to quickly predict an isolate’s 
drug sensitivities from genomic data will lead to faster 
prescribing of an appropriately tailored treatment 
regimen, in turn leading to a lower risk of emergent 
resistance and more rapid conversion to a non-infectious 
state, enabling a patient to resume a normal lifestyle.
The key to implementation of bespoke treatment 
based on whole-genome sequencing is to have a 
comprehensive database of resistance-associated 
mutations. Although some canonical mutations 
in genes such as inhA and rpoB bring about several 
drug-resistant phenotypes of tuberculosis, many 
other resistance mutations exist, some of which have 
been catalogued in databases such as TBDreamDB5 
and MUBII-TB-DB,6 but many of which are unknown. 
Walker and colleagues present both an extended 
range of known resistance mutations and an 
algorithm to discover new mutations.3 In their study, 
they examine a large dataset of 3651 M tuberculosis 
genomes representing diﬀ erent genetic lineages, 
each with phenotypic results from drug-susceptibility 
testing. They selected 2099 isolates as a training 
dataset and developed an algorithm to scan for 
mutations in 23 genes associated with antibiotic 
resistance. The algorithm identiﬁ ed 991 mutations 
potentially associated with resistance; when these 
were combined with phenotypic data, 120 mutations 
ultimately emerged as being potentially predictive 
of resistance. Using these mutations as the basis of a 
classiﬁ er to predict phenotypes in the 1552 validation 
genomes, Walker and colleagues were able to assign 
nine of 10 validation cases to the correct class—
sensitive or resistant—with a mean 92·3% sensitivity 
(95% CI 90·7–93·7) and 98·4% speciﬁ city (98·1–98·7). 
The investigators then re-ran the algorithm on the 
complete set of 3651 genomes, increasing the pool of 
resistance-associated mutations to 232 and improving 
predictive capacity—assigning 96·1% of isolates to 
the correct class with only a negligible decrease in 
speciﬁ city. 
This study is an important ﬁ rst step towards routine 
genomic prediction of antibiotic susceptibility 
in tuber culosis. A reliable catalogue of resistance 
mutations is needed if whole-genome sequencing is 
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to be standardised and validated for use in the clinical 
setting, as is a protocol (such as the algorithm outlined 
by Walker and colleagues) that can continually be 
retrained to identify novel resistance-associated 
mutations when new genomes become available. 
To sustain the momentum of this approach, the 
community of health-care specialists in tuberculosis 
should commit to sharing genome sequences through 
public repositories, including clinical metadata 
such as results from drug-susceptibility testing. As 
sequencing moves from the research laboratory into 
the reference laboratory, a clash of values might 
occur between the open-data mindset of genomics 
research and public health’s inherent concern with 
data stewardship and privacy. However, the two 
communities should navigate the new landscape 
together to create centralised, public-facing genomic 
repositories containing the metadata needed to 
train and test new predictive tools, and maintaining 
patient conﬁ dentiality and addressing issues of data 
ownership and attribution. 
Can genomics ever completely replace phenotypic-
resistance testing? Perhaps not, because of many 
reasons—the suite of resistance-associated mutations 
for a speciﬁ c organism might not ever be completely 
known; compensatory mutations can be diﬃ  cult to 
tease out from those causing resistance; and the role 
of minor variants and other inﬂ uences on resistance, 
such as expression levels, has not yet been fully 
described. Even so, whole-genome sequencing oﬀ ers 
the potential of rapid ﬁ rst-pass phenotyping and, in 
a world where multidrug-resistant tuberculosis is a 
growing problem, an opportunity to rationally tailor 
treatment to individuals. 
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Antibiotics, copayments, and antimicrobial resistance: 
investment matters
Antibiotics are unequivocally one of the greatest 
innovations in medicine, but the threat of resistance 
is approaching a tipping point. In Europe alone, health 
care and productivity costs  are estimated at more than 
€1·5 billion per year,1 with costs in the USA estimated 
at US$55 billion.2 Accurate data from low-income and 
middle-income settings are insuﬃ  cient.3,4 With only 
two new classes of antibiotics developed since the 
1970s, the possibility of a world without antibiotics is 
a global concern. If the absence of new antibiotics and 
the lack of innovation continue, we are in danger of 
entering the post-antibiotic era, with routine and life-
saving care disrupted, such as cancer chemotherapy, 
surgical procedures, and treatment of infection in 
neonates.
Innovation in new classes of antibiotics has been 
unattractive for the biopharmaceutical industry 
because new drugs would probably be used only 
after existing antimicrobial agents were exhausted.5,6 
The Oﬃ  ce of Health Economics published ﬁ ndings 
showing that the value of a new musculoskeletal 
drug can be up to 20 times higher than that of a new 
antibiotic to the developing pharmaceutical company.7 
Clearly these ﬁ gures are not aligned with disease 
burden and pandemic potential of resistant infections, 
and innovation is desperately needed.
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